DelveInsight’s, “Type 1 Diabetes Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Type 1 Diabetes Pipeline Report

• DelveInsight’s Type 1 Diabetes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
• The leading companies working in the Type 1 Diabetes Market include Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.
• Promising Type 1 Diabetes Pipeline Therapies in the various stages of development include Euglycemic clamp with BC Combo THDB0207, ORMD-0801 Treatment A, Dapagliflozin, Mylan’s insulin glargine, Lantus®, and others.
• September 2023: Eli Lilly and Company announced a study of Phase 1 clinical trials for Glucagon Nasal Powder [Baqsimi]. The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets into the bloodstream.
• October 2023: Dompe Farmaceutici SpA announced a study of phase 2 clinical trials for Ladarixin. The study is a phase 2, multicenter, double-blind, placebo-controlled study. It will randomize approximately 75 adult patients with new-onset type 1 diabetes (T1D) and preserved beta-cell function (fasting C-peptide >0.205 nmol/l) at baseline. Patients will be assigned (2:1) to receive either oral ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off – treatment group) or placebo (control group).

 

Request a sample and discover the recent advances in Type 1 Diabetes Treatment Drugs @ Type 1 Diabetes Pipeline Report

 

In the Type 1 Diabetes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Type 1 Diabetes Overview

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth.

 

Find out more about Type 1 Diabetes Therapeutics Assessment @ Type 1 Diabetes Preclinical and Discovery Stage Products

 

Type 1 Diabetes Emerging Drugs Profile

• Teplizumab: Prevention Bio
• Emricasan: Histogen
• VX-880: Vertex Pharmaceuticals

 

Type 1 Diabetes Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Type 1 Diabetes therapies. The Type 1 Diabetes companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio.

 

Learn more about the emerging Type 1 Diabetes Pipeline Therapies @ Type 1 Diabetes Clinical Trials Assessment

 

Table of Content

1. Introduction
2. Executive Summary
3. Type 1 Diabetes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Type 1 Diabetes– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Teplizumab: Provention Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. TTP 399: Novo Nordisk
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SBP 101: Takeda Oncology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Eflornithine oral: Panbela Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Type 1 Diabetes Key Companies
21. Type 1 Diabetes Key Products
22. Type 1 Diabetes- Unmet Needs
23. Type 1 Diabetes- Market Drivers and Barriers
24. Type 1 Diabetes- Future Perspectives and Conclusion
25. Type 1 Diabetes Analyst Views
26. Type 1 Diabetes Key Companies
27. Appendix

 

For further information on the Type 1 Diabetes Pipeline therapeutics, reach out to Type 1 Diabetes Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking